(RTTNews) - Antengene Corporation Limited (6996.HK) announced that China National Medical Products Administration or NMPA has approved the investigational new drug application for the Phase Ib/II ...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter LAWRENCEVILLE, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- IMUNON (IMNN), Inc. ...

Quantum BioPharma Ltd. has announced an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application package for Lucid-21-302 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address ...

HOUSTON, TX / ACCESS Newswire / March 4, 2026 / BrYet US, Inc. ("BrYet") - a biotechnology innovator focused on ...

MALVERN, Pa.--(BUSINESS WIRE)--NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today ...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to advance ...

ABL Bio Inc. has submitted an IND application to the FDA seeking clearance to begin a phase I trial of ABL-209 (NEOK-002). Pending approval, the trial is expected to begin by mid-year in the U.S.

Neurizon files an Investigational New Drug application with US FDA for lead drug candidate NUZ-001 Filing marks a pivotal step in enabling start of phase 2/3 trial of NUZ-001 within the Healey ALS ...